CDK9 and prostate carcinoma: In addition to over-riding programmed cell death responses via upregulation of anti-apoptotic factors, CDK9 also promotes the expression and/or activity of oncogenic transcription factors such as MYC, NF-κB, BRD4, and STAT3, all of which are established drivers of prostate cancer progression [15–19].